Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.
News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.
Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.
Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.
Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.
A jury in the United States District Court for the Central District of California ruled that Elysium Health breached its contract with ChromaDex, leading to damages of
ChromaDex Corp. (NASDAQ: CDXC) has formed a partnership with Sinopharm Xingsha Pharmaceuticals to facilitate cross-border sales of its product, Tru Niagen®, in mainland China. Sinopharm Xingsha is a key subsidiary of Sinopharm Group, involved in drug and health supplement distribution. With a projected 45.2% of China’s population over 50 by 2040, the demand for Tru Niagen® is expected to rise significantly. The collaboration also aims to obtain Health Food Registration in China, enhancing market accessibility for Tru Niagen®, a top NAD+ booster.
ChromaDex Corp. (NASDAQ:CDXC) announced significant preclinical findings from its External Research Program focusing on nicotinamide riboside (NR). Studies indicate NR's protective effects on retinal ganglion cells in glaucoma, improvement in Alzheimer’s disease models through enhanced brain NAD+ levels, and cardioprotective benefits in ischemia-reperfusion injury models. Additionally, ChromaDex is supporting clinical trials investigating NR's impact on neurological symptoms in ataxia-telangiectasia and skeletal muscle metabolism. These advancements highlight NR’s potential in addressing age-related conditions.
ChromaDex (NASDAQ:CDXC) announced plans to appeal a September 14 ruling in its patent infringement lawsuit against Elysium Health in the District Court of Delaware. The company holds exclusive rights to nicotinamide riboside (NR) through U.S. Patents 8,383,086 and 8,197,807. Additionally, ChromaDex's product Niagen® is supported by 13 clinical trials and approved by major regulatory bodies including the U.S. FDA and Health Canada. Another lawsuit against Elysium is set for trial on September 21 in California.
ChromaDex Corp. (NASDAQ:CDXC) reported Q2 2021 financial results showing net sales of $17.7 million, a 16% increase year-over-year. Tru Niagen® sales reached $15.4 million, up 31%. The gross margin improved to 61.1%, reflecting effective cost control. However, the company recorded a net loss of $(5.6) million or $(0.08) per share, compared to a loss of $(3.7) million last year. Adjusted EBITDA was $0.6 million, a slight improvement. The company anticipates continued revenue growth and is investing in R&D and marketing.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on August 3, 2021, at 4:30 p.m. ET to discuss its Q2 financial results ending June 30, 2021. The financial results will be released after the market closes on the same day. Interested participants should join 10 minutes early. The call will also provide a general business update. A replay will be available after the call. ChromaDex specializes in healthy aging and is known for its NAD+ precursor, nicotinamide riboside (Niagen®), featured in its Tru Niagen® product.
ChromaDex Corp. (NASDAQ:CDXC) announced results from four preclinical studies on nicotinamide riboside (NR), showcasing its benefits for healthy aging. Through its ChromaDex External Research Program (CERP™), the company has established over 225 research agreements, leading to 12 clinical and 66 preclinical studies. Notable findings include NR's role in preventing bone loss in aging mice and restoring metabolic capacity in aged stem cells. Additionally, NR is shown to reduce neuroinflammation and mitigate alcohol's harmful effects. ChromaDex has invested over $35 million in NR research and holds over 20 patents.
ChromaDex Corp. (NASDAQ:CDXC) has launched its flagship product, Tru Niagen®, in Walmart, making it available in 3,800 stores across the U.S. This marks Walmart as the first major U.S. retailer to stock the clinically studied NAD+ booster. Customers can choose between 100mg and 300mg serving sizes, both available for in-store and online purchases. Tru Niagen® aims to elevate NAD+ levels, which decline with age, by up to 50%. The product is supported by extensive safety and efficacy research and is recognized by multiple health authorities.
ChromaDex reported Q1 2021 net sales of $14.7 million, a 2% increase year-over-year, driven by a 12% growth in Tru Niagen® sales. The gross margin improved to 62.9%, up 500 basis points. However, the company posted a net loss of $7.4 million, or $0.12 per share, a deeper loss compared to Q1 2020's $5.9 million net loss. Operating expenses rose to $16.6 million, primarily due to increased selling and marketing costs. Looking ahead, ChromaDex anticipates steady revenue growth and continued margin improvement, with new strategic partnerships expected to boost sales.
ChromaDex Corp. (NASDAQ:CDXC) has entered into a strategic supply agreement for its patented ingredient Niagen® with Ro, a healthcare technology company. This agreement gives Ro rights to use Niagen® in specially formulated products aimed at promoting healthy aging. Niagen® is known to increase NAD+ levels, which decline with age. Both companies expressed enthusiasm about the partnership, with ChromaDex's focus on advancing health through research on nicotinamide adenine dinucleotide (NAD+).